JP2018538367A - ホルミルペプチド受容体２／リポキシンａ４受容体（ｆｐｒ２／ａｌｘ）の心臓疾患を治療するための標的設定 - Google Patents

ホルミルペプチド受容体２／リポキシンａ４受容体（ｆｐｒ２／ａｌｘ）の心臓疾患を治療するための標的設定 Download PDF

Info

Publication number
JP2018538367A
JP2018538367A JP2018545568A JP2018545568A JP2018538367A JP 2018538367 A JP2018538367 A JP 2018538367A JP 2018545568 A JP2018545568 A JP 2018545568A JP 2018545568 A JP2018545568 A JP 2018545568A JP 2018538367 A JP2018538367 A JP 2018538367A
Authority
JP
Japan
Prior art keywords
alx
fpr2
treatment
receptor
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2018545568A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018538367A5 (enExample
Inventor
ジャセク・オストロウスキー
リカルド・ガルシア
ニコラス・アール・ワーツ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Co
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of JP2018538367A publication Critical patent/JP2018538367A/ja
Publication of JP2018538367A5 publication Critical patent/JP2018538367A5/ja
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4152—1,2-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. antipyrine, phenylbutazone, sulfinpyrazone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2018545568A 2015-11-24 2016-11-21 ホルミルペプチド受容体２／リポキシンａ４受容体（ｆｐｒ２／ａｌｘ）の心臓疾患を治療するための標的設定 Withdrawn JP2018538367A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562259498P 2015-11-24 2015-11-24
US62/259,498 2015-11-24
PCT/US2016/063036 WO2017091496A1 (en) 2015-11-24 2016-11-21 Targeting of the formyl-peptide receptor 2/lipoxin a4 receptor (fpr2/alx) for treatment of heart disease

Publications (2)

Publication Number Publication Date
JP2018538367A true JP2018538367A (ja) 2018-12-27
JP2018538367A5 JP2018538367A5 (enExample) 2019-12-19

Family

ID=57544530

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018545568A Withdrawn JP2018538367A (ja) 2015-11-24 2016-11-21 ホルミルペプチド受容体２／リポキシンａ４受容体（ｆｐｒ２／ａｌｘ）の心臓疾患を治療するための標的設定

Country Status (13)

Country Link
US (1) US20180325869A1 (enExample)
EP (1) EP3380091A1 (enExample)
JP (1) JP2018538367A (enExample)
KR (1) KR20180081528A (enExample)
CN (1) CN108348479A (enExample)
AU (1) AU2016359463A1 (enExample)
BR (1) BR112018010155A8 (enExample)
CA (1) CA3006291A1 (enExample)
EA (1) EA201891007A1 (enExample)
IL (1) IL259468A (enExample)
MX (1) MX2018005756A (enExample)
SG (1) SG11201803816RA (enExample)
WO (1) WO2017091496A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3414227B1 (en) 2015-12-10 2021-11-24 Bristol-Myers Squibb Company Piperidinone formyl peptide 2 receptor and formyl peptide 1 receptor agonists
KR102623473B1 (ko) 2017-06-09 2024-01-09 브리스톨-마이어스 스큅 컴퍼니 피페리디논 포르밀 펩티드 2 수용체 및 포르밀 펩티드 1 수용체 효능제
WO2018227067A1 (en) 2017-06-09 2018-12-13 Bristol-Myers Squibb Company Cyclopropyl urea formyl peptide 2 receptor and formyl peptide 1 receptor agonists
CN110997653B (zh) 2017-06-09 2023-06-06 百时美施贵宝公司 芳基杂环哌啶酮甲酰肽2受体和甲酰肽1受体激动剂
US11008301B2 (en) 2017-06-09 2021-05-18 Bristol-Myers Squibb Company Piperidinone formyl peptide 2 receptor agonists
US10676431B2 (en) 2018-03-05 2020-06-09 Bristol-Myers Squibb Company Phenylpyrrolidinone formyl peptide 2 receptor agonists
CN113166134B (zh) 2018-11-26 2024-06-14 百时美施贵宝公司 作为甲酰肽2受体激动剂的吡咯烷酮衍生物
IL299680A (en) 2020-07-09 2023-03-01 Bristol Myers Squibb Co Pyrazolone formyl peptide 2 receptor agonists
JP7802765B2 (ja) 2020-08-12 2026-01-20 ブリストル－マイヤーズ スクイブ カンパニー オキソピロリジン尿素ｆｐｒ２アゴニスト

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2492167C2 (ru) * 2007-12-18 2013-09-10 Актелион Фармасьютиклз Лтд Производные аминотриазола в качестве агонистов alх
KR101905927B1 (ko) * 2010-11-17 2018-10-08 이도르시아 파마슈티컬스 리미티드 가교된 스피로［２．４］헵탄 에스테르 유도체
CA2871334A1 (en) * 2012-05-16 2013-11-21 Actelion Pharmaceuticals Ltd 1-(p-tolyl)cyclopropyl substituted bridged spiro[2.4]heptane derivatives as alx receptor agonists
EP3414227B1 (en) * 2015-12-10 2021-11-24 Bristol-Myers Squibb Company Piperidinone formyl peptide 2 receptor and formyl peptide 1 receptor agonists
US10676431B2 (en) * 2018-03-05 2020-06-09 Bristol-Myers Squibb Company Phenylpyrrolidinone formyl peptide 2 receptor agonists

Also Published As

Publication number Publication date
US20180325869A1 (en) 2018-11-15
KR20180081528A (ko) 2018-07-16
CA3006291A1 (en) 2017-06-01
EP3380091A1 (en) 2018-10-03
BR112018010155A8 (pt) 2019-02-26
WO2017091496A1 (en) 2017-06-01
SG11201803816RA (en) 2018-06-28
MX2018005756A (es) 2018-08-01
CN108348479A (zh) 2018-07-31
IL259468A (en) 2018-07-31
EA201891007A1 (ru) 2018-11-30
AU2016359463A1 (en) 2018-07-12
BR112018010155A2 (pt) 2018-11-21

Similar Documents

Publication Publication Date Title
JP2018538367A (ja) ホルミルペプチド受容体２／リポキシンａ４受容体（ｆｐｒ２／ａｌｘ）の心臓疾患を治療するための標的設定
Wang et al. Coriolus versicolor alleviates diabetic cardiomyopathy by inhibiting cardiac fibrosis and NLRP3 inflammasome activation
Liu et al. Autophagy activation attenuates angiotensin II-induced cardiac fibrosis
Liu et al. Rivaroxaban suppresses the progression of ischemic cardiomyopathy in a murine model of diet-induced myocardial infarction
JP6440212B2 (ja) メトホルミン及びジヒドロケルセチンを含む組み合わせ医薬、及びがんの治療のための使用
CN113318110B (zh) 一种csf-1r激酶抑制剂的用途
CN107072972B (zh) 用伊非曲班治疗心脏纤维化的组合物和方法
JP2020520948A (ja) 心不全の治療用のホルミルペプチド受容体２／リポキシンａ４受容体（ｆｐｒ２／ａｌｘ）アゴニストの新規な使用
US20250152671A1 (en) Medical composition for treating patients exhibiting cardiac decompensation
JP7844766B2 (ja) 抗特発性肺線維症薬ニンテダニブの結核を治療するための使用
KR102354243B1 (ko) 트롬복산-a2 수용체 길항제를 이용한 근위축증 치료 조성물 및 방법
KR20140022052A (ko) 심근 경색 후 환자에서의 심부전 및 부정맥 치료를 위한 ａ２ｂ 아데노신 수용체 안타고니스트의 용도
WO2017189885A1 (en) Ifetroban treatment for systemic sclerosis
CN108472333B (zh) 组合
US20230114408A1 (en) Methods of modulating t-cell activation using estrogen receptor beta (erb) agonists
CN104220083A (zh) 用于治疗动脉硬化性血管疾病的方法和组合物
EP4117660B1 (en) Methods of modulating t-cell activation and treating chronic heart failure using carboranes
JP7233087B2 (ja) 抗動脈硬化剤
WO2026064493A1 (en) Inhibition of farnesyltransferase to treat cardiomyopathy and heart failure
HK40080138A (en) Methods of modulating t-cell activation using carboranes and carborane analogs
WO2024073499A2 (en) Compositions and methods for treating graft-related arrhythmia
WO2026057747A1 (en) Therapeutic use of nlrp3 inflammasome pathway inhibitor compounds
WO2025056188A1 (en) Relaxin medication
CN116236477A (zh) 溶血磷脂酸受体5拮抗剂在制备心脏保护药物中的应用
EP3072514A1 (en) Novel oral anticoagulants (NOACs) for preventing development and aggravation of atrial fibrillation

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20191106

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20191106

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20200513